PUBLICATION

The Heparan Sulfate Binding Peptide in Tumor Progression of Triple-Negative Breast Cancer

Authors
Melo, C.M., Wang, H., Fujimura, K., Strnadel, J., Meneghetti, M.C.Z., Nader, H.B., Klemke, R.L., Pinhal, M.A.S.
ID
ZDB-PUB-210824-8
Date
2021
Source
Frontiers in oncology   11: 697626 (Journal)
Registered Authors
Klemke, Richard
Keywords
anti-angiogenic, breast cancer (BC), breast neoplasia, glycosaminoglycans, phage display
MeSH Terms
none
PubMed
34422650 Full text @ Front Oncol
Abstract
Angiogenesis is the formation of new vessels from pre-existing vasculature. The heparan sulfate chains from endothelial cell proteoglycans interact with the major angiogenic factors, regulating blood vessels´ formation. Since the FDA´s first approval, anti-angiogenic therapy has shown tumor progression inhibition and increased patient survival. Previous work in our group has selected an HS-binding peptide using a phage display system. Therefore, we investigated the effect of the selected peptide in angiogenesis and tumor progression. The HS-binding peptide showed a higher affinity for heparin N-sulfated. The HS-binding peptide was able to inhibit the proliferation of human endothelial umbilical cord cells (HUVEC) by modulation of FGF-2. It was verified a significant decrease in the tube formation of human endothelial cells and capillary formation of mice aorta treated with HS-binding peptide. HS-binding peptide also inhibited the formation of sub-intestinal blood vessels in zebrafish embryos. Additionally, in zebrafish embryos, the tumor size decreased after treatment with HS-binding peptide.
Genes / Markers
Figures
Show all Figures
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Antibodies
Orthology
Engineered Foreign Genes
Mapping